Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial (Q48806296)

15 February 2018

title

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial (English)

1 reference

15 February 2018

1

David A Reardon

1 reference

15 February 2018

2

Patrick Y Wen

1 reference

15 February 2018

author name string

W K Alfred Yung

3

1 reference

15 February 2018

Lori Berk

4

1 reference

15 February 2018

Narayana Narasimhan

5

1 reference

15 February 2018

Christopher D Turner

6

1 reference

15 February 2018

Timothy Clackson

7

1 reference

15 February 2018

Victor M Rivera

8

1 reference

15 February 2018

Michael A Vogelbaum

9

1 reference

15 February 2018

publication date

30 October 2011

1 reference

15 February 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

15 February 2018

volume

69

1 reference

15 February 2018

issue

4

1 reference

15 February 2018

page(s)

849-860

1 reference

15 February 2018

The 2007 WHO classification of tumours of the central nervous system

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Lessons learned in the development of targeted therapy for malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

mTOR signaling and drug development in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Signal transduction molecules in gliomas of all grades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

The biology behind mTOR inhibition in sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

eIF4E--from translation to transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1773-Y

10.1007/S00280-011-1773-Y

21 January 2018

Identifiers

DOI

1 reference

15 February 2018

release_j66fgfzt5vfv3alakuynu2724m

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/j66fgfzt5vfv3alakuynu2724m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

15 February 2018